Condition

MSA (3)

Parkinson's Disease (PD) (1)

Pure Autonomic Failure (PAF) (1)

Symptomatic Neurogenic Orthostatic Hypotension (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Terminated (1)

Sign in for free

Phase

phase 1/phase 2 (2)

phase 3 (1)

Sponsor

Brigham and Women's Hospital (1)

Mayo Clinic (1)

Theravance Biopharma (1)

Collaborator

Food and Drug Administration (FDA) (1)

National Institute of Neurological Disorders and Stroke (NINDS) (1)

Intervention

[f-18]pbr06 (1)

ampreloxetine (1)

autologous mesenchymal stem cells (1)

placebo (1)

Study Documents

Intervention Type

drug (2)

biological (1)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

msa

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD) Trial in Worldwide (ampreloxetine, Placebo)

Terminated

Has Results

Symptomatic Neurogenic Orthostatic Hypotension
+3 more

ampreloxetine
Placebo

Sun City, Arizona
+81 more

Dec 29, 2022

MSA Trial in Rochester (Autologous Mesenchymal Stem Cells)

Active, not recruiting

MSA

Autologous Mesenchymal Stem Cells

Rochester, Minnesota

Mayo Clinic in Rochester

Sep 7, 2021

MSA Trial in Boston ([F-18]PBR06)

Completed

MSA

[F-18]PBR06

Boston, Massachusetts

Movement Disorders Clinic, 60 Fenwood Road

Apr 22, 2021